Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kent Webb

Vascular Surgery Jacksonville, TX Medical Doctor

NPI 1104892926 CMS profile 321844

2026 S Jackson St, Jacksonville, TX 75766

Open in the dashboard

General payments

$101,476

265 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kent Webb of Jacksonville, TX is reported in the CMS Open Payments database as having received $101,476 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $672 34
2024 General $968 29
2023 General $10,713 40
2022 General $20,833 51
2021 General $16,905 21
2020 General $5,150 13
2019 General $46,234 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kent Webb
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Kent Webb were reported at $672. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Kent Webb Vascular Surgery median Middle half National median
2019 $46,234 $796 $226–$2,363 $163
2020 $5,150 $348 $118–$1,110 $114
2021 $16,905 $471 $158–$1,421 $132
2022 $20,833 $725 $222–$2,183 $149
2023 $10,713 $836 $257–$2,440 $160
2024 $968 $909 $252–$2,619 $164
2025 $672 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $96,783 87 payments
  2. AngioDynamics, Inc. $2,086 77 payments
  3. Bard Peripheral Vascular, Inc. $756 21 payments
  4. W. L. Gore & Associates, Inc. $449 18 payments
  5. Philips Electronics North America Corporation $347 13 payments
  6. Boston Scientific Corporation $312 21 payments
  7. Silk Road Medical, Inc. $159 1 payment
  8. Cardiovascular Systems Inc. $111 7 payments
  9. Medtronic, Inc. $88 1 payment
  10. Shockwave Medical, Inc $68 3 payments
  11. Other $318 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $88,708 40 payments
  2. Travel and Lodging $6,272 22 payments
  3. Food and Beverage $6,162 200 payments
  4. Consulting Fee $300 1 payment
  5. Education $35 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $96,783 87 payments
  2. AURYON LASER SYSTEM 100-120 VAC Pad $1,436 69 payments
  3. Venclose Maven Catheter $536 14 payments
  4. VenaCure 1470 Pro $374 5 payments
  5. IGT D Peripheral $226 10 payments
  6. Auryon Laser System 100-120 Vac Et $225 1 payment
  7. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $159 1 payment
  8. ENROUTE Transcarotid Stent $159 1 payment
  9. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $159 1 payment
  10. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $159 1 payment
  11. Other $1,764 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,345

Median for Vascular Surgery: 122

Drug cost

$262,442

Median for Vascular Surgery: $14,135

Branded share of claims

43.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 288 $229,469
Eliquis Apixaban Brand 31 $22,123
Cilostazol Generic 228 $3,528
Torsemide Generic 224 $3,169
Clopidogrel Clopidogrel Bisulfate Brand 193 $1,251
Potassium Chloride Generic 116 $1,076
Gabapentin Generic 45 $725
Rosuvastatin Calcium Generic 73 $407
Furosemide Generic 19 $184
Acetaminophen-Codeine Acetaminophen With Codeine Brand 51 $180

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$166,864

Medicare's payments for the services billed

Medicare patients

667

Average age 75

Services billed

2,212

365 women, 302 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 43%
Diabetes 40%
Chronic kidney disease 32%
COPD 28%
Atrial fibrillation 27%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record